Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year): lines of therapy
4 standard-of-care settings across 4 lines and 4 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers | FRα | KMT2A | Risk group |
|---|---|---|---|---|
| Early / localised | · | · | · | 1 |
| Advanced, first line | 1 | · | · | · |
| Maintenance | · | · | 1 | · |
| Third line and beyond | · | 1 | · | · |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| Risk group | High risk | Allogeneic transplant in first remission after blinatumomab and consolidation. | NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version) | 92 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Induction | Interfant backbone: a week of prednisone, then dexamethasone, vincristine, cytarabine, daunorubicin and asparaginase with intrathecal therapy. | NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version) | 79 |
Maintenance
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| KMT2A | Post-induction, KMT2A-rearranged | One 28-day course of blinatumomab after induction (Interfant-21), then Interfant-06 consolidation and maintenance. | NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version) | 85 |
Third line and beyond
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| FRα | Relapsed or refractory | Revumenib (approved from the age of one) or trials of menin inhibitors; blinatumomab or CD19 CAR T-cells; transplant. | NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (health professional version) | 92 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.